Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Clinical trial NCT05105841 · COMPLETED

Trial details

NCT number: NCT05105841
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Start date: 2021-11-08
Primary completion: 2025-10-09
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.